Group 3:Infusion 3 dose levels: 3.0x10^6 cells/kg, 5.0x10^6 cells/kg, 7.0x10^6 cells/kg
Sponsors
The Affiliated Hospital of Nantong University
Conditions
Advanced solid tumorR/R CD19-positive B-cell Malignant Tumors
Phase 1
Phase the Safety and Tolerability of CD19 Universal Chimeric Antigen Receptor T Cells in Subjects with R/R CD19 positive B cell malignant tumors
Active, not recruitingChiCTR2000040018
Start: 2021-01-01Updated: 2021-01-05
A clinical study to evaluate the safety and effectiveness of Mesothelin UCAR-T cell injection in the treatment of advanced solid tumors
Active, not recruitingChiCTR2000040007
Start: 2021-01-01Updated: 2021-01-05